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Objective/background: In obstructive sleep apnea (OSA), long-term adherence to treatment is crucial. This
prospective single-center study investigated factors associated with long-term adherence to mandibular
repositioning device (MRD) therapy.
Patients/methods: All OSA patients who had MRD treatment initiated in the previous year were
prospectively contacted to evaluate long-term effectiveness and compliance. Long-term adherence was
based on continuation of treatment (yes/no). Predictors of long-term adherence were analyzed using an
adjusted multivariate analysis.
Results: Median follow-up was 1002 days (interquartile range: 668e1345) in 279 patients (age 58 [50
e64] years); 63% of patients were continuing MRD treatment with a good efﬁcacy, tolerability and
compliance over time. In some patients, relapse of nocturia was observed while efﬁcacy was maintained
for snoring and somnolence. In adjusted multivariate analysis, signiﬁcant predictors of continuing MRD
treatment were early 50% reduction in AHI (odds ratio [OR] 2.73, 95% conﬁdence interval [CI] 1.466
e5.10; p ¼ 0.0002) and complete symptom resolution (OR 3.83, 95% CI 1.74e8.48; p ¼ 0.0014). In the 37%
of patients who stopped MRD treatment, median treatment duration was 351 (174e752) days. The main
reasons for late stopping of treatment were inefﬁcacy (26.2%), discomfort (25.2%) and side effects (21.4%).
Conclusions: After three years, MRD was effective for the two-thirds of OSA patients who continued
treatment. Relapse of nocturia might be an early signal of MRD wear that may explain long-term
cessation of treatment in some patients. Short-term control of OSA by MAD was predictive of long-
term efﬁciency. The major criteria were a 50% reduction in AHI and complete symptom resolution at
short-term evaluation.
© 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).icine (“Service d’Exploration
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Obstructive sleep apnea (OSA) is characterized by recurrent
collapse of the upper airway during sleep. Obstructive apneas and
hypopneas lead to oxygen desaturation, sleep fragmentation and
increased sympathetic tone, which in turn induce a variety of sys-
temic consequences [1]. OSA has been associated with cardiovas-
cular morbidity [2], sleepiness-related accidents [3] and cognitivearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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function [4]. The rate of cardiovascular events can be signiﬁcantly
reduced by treatment with continuous positive airway pressure
(CPAP), which is considered the standard of care. However, more
than 40% of patients do not tolerate CPAP or use it irregularly [5].
Mandibular repositioning devices (MRDs) protrude the
mandible and tongue, and enlarge and stabilize the upper airways
during sleep [6]. Over the short term, MRDs are less efﬁcient than
CPAP at reducing respiratory events, but are associated with better
long-term compliance and similar efﬁcacy on symptoms and
quality of life (QOL) [7], making MRDs a viable alternative to CPAP
for the treatment of OSA [8,9]. Two long-term studies, both based
on observational follow-up of initially randomized trials, compared
MRD to CPAP and reported smaller reductions in the apnea-
hypopnea index (AHI) but similar effects on symptoms compared
with CPAP, akin to ﬁndings over the shorter term [10,11]. Possible
side effects of long-term MRD use include dental adverse events,
such as occlusal changes [12], which may lead to poor compliance
[12e14]. Practical considerations may also limit long-term
compliance. In fact, there is a lack of data on the long-term clin-
ical effects of MRDs, and particularly on long-term compliance with
therapy. The main objective of this study was to provide long-term
data onMRD use in a large cohort of OSA patients treated in routine
clinical practice, and to evaluate if some factors could help physi-
cians predict long-term adherence.
2. Methods
This observational, single-center study was conducted at
the Pitie-Salpe^triere Hospital, France, was in accordance with
Declaration of Helsinki principles, and consisted of a long-term
evaluation of MRD effects based on one prospective contact. In
addition, baseline data, titration process and short-term evaluation
ofMRDwere extracted frompatient's medical records at the time of
the study. The Pitie-Salpe^triere Hospital is a large (n ¼ 2146 beds)
clinical and university center where OSA management is based on
integrated care. Around 400 OSA patients per year are newly
diagnosed (on 700 polysomnographies for OSA suspicion) and
treated by either CPAP or MRD. The majority of patients that are
treated by CPAP and MRD treatment represent around 15e20% of
treatment indications. In this study, a dedicated dental specialist
managed MRD treatment of OSA patients and worked closely with
sleep specialists; MRD treatment and collection of data about efﬁ-
cacy, tolerability and compliance were procedure-based. Ethics
Committee approval and data processing authorization were
obtained for the study (CCTIRS, Comite Consultatif sur le Traite-
ment de l'Information en matiere de Recherche dans le domaine de
la Sante; CNIL, Commission Nationale de l’Informatique et des
Libertes). All patients were provided with information about the
study and were free to refuse participation.
2.1. Patients and eligibility to MRD treatment
Eligibility for MRD treatment in this study was based on
the sleep specialist's evaluation (clinical evaluation and poly-
somnography) followed by the dental specialist's evaluation
(clinical evaluation and panoramic X-ray). All OSA patients referred
to the dental specialist by the sleep specialist with an indication for
anMRDwere screened. All patients having been treated byMRD for
at least one day and who had started treatment at least one year
previously (those who were still using the device at the time of the
prospective contact for our study and patients who had stopped
treatment in the period between initiation and our prospective
contact) and consented to take part in the study were included in
the analysis. Patients who did not initiate the MRD treatment werescreened but not included. Indication of MRD treatment, was based
on French indications in OSA (patients with an AHI >30/h or 30/h
with severe excessive sleepiness in patients intolerant to or
refusing CPAP; OR 5/h  AHI  30/h, mild to moderate excessive
sleepiness and without severe cardiovascular morbidity). The
dental specialist conﬁrmed or disconﬁrmed the indication of MRD.
He performed an in-depth clinical evaluation (number of teeth,
dental mobility, periodontal and temporomandibular evaluations)
and a radiological evaluation based on a panoramic X-ray to
detect any other dental or periodontal diseases. For all patients,
measurements of mandibular advancement from end to end in
maximum protrusion, maximal jaw propulsion, dental overjet and
dental overbite, were completed. Contraindications were less than
eight healthy teeth per jaw, periodontal disease, and temporo-
mandibular joint disease. A cephalometric evaluation was not
required even if some patients had this evaluation (not collected in
this study).
2.2. Data ﬁle collection for baseline data, titration process and
short-term evaluation
Baseline variables, MRD-related data (treatment initiation date,
type of MRD and titration), short-term clinical and AHI evaluation,
tolerability and compliance data were obtained from patient
medical records. For PSG data, American Academy of Sleep Medi-
cine (AASM) guidelines [15] were used to deﬁne respiratory events.
Apnea was deﬁned as absence of airﬂow for at least 10 s, hypopnea
as a reduction of airﬂow by at least 30% associated with a decrease
in oxygen saturation of three percent or more, or with arousal.
2.3. Prospective long-term follow-up
Prospective long-term follow-up consisted of phone contact to
obtain record of MRD effects. The ﬁrst question determined
whether the MRD was still being used or not. In patients who
stopped MRD treatment, the cessation date, main reasons for MRD
discontinuation and therapeutic changeswere recorded. In patients
continuing MRD treatment, global clinical efﬁcacy (answer yes/no
to the following question: “Is your device efﬁcient on OSA symp-
toms?”), OSA symptoms, the Epworth Sleepiness Scale (ESS) score,
MRD-related side effects, MRD-related compliance (use time per
night, number of nights/weekwith use and reasons for lowuse) and
patient satisfaction with MRD therapy were assessed. Satisfaction
over the preceding four weeks of treatment was determined based
on three general items (global satisfaction, quality of sleep, treat-
ment manageable) scored on a scale from zero (very bad) to ten
(excellent) and four items compared with CPAP (comfort, reduction
in symptoms, compliance, social life) scored on a scale from zero
(MRD worse than CPAP) to ten (MRD very superior to CPAP).
2.4. Statistical analysis
Measures are presented as median and interquartile range for
quantitative variables and number and percentage for qualitative
variables. Comparison between patients with vs. without contin-
uation of treatment was performed as follows: group description
was performed using mean ± standard deviation (SD) for quanti-
tative variables and percentages for qualitative variables. Univariate
comparisons were performed using Student's t tests for quantita-
tive variables and Chi-square tests for qualitative variables. Two
logistic models were created to determine predictors of treatment
continuation, the ﬁrst including the whole study population and
the second including only patients with a short-term PSG evalua-
tion. Variables with a p-value lower than 0.10 in the univariate
analysis were entered in the stepwise logistic regressions, and
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retained in the ﬁnal models. All computations were performed
using SAS V9.3 (SAS Institute Inc, Cary, NC, USA). Cessation of MRD
treatment over time was estimated by the Kaplan-Meier method.
3. Results
3.1. Baseline data, titration and short-term evaluation
A total of 458 OSA patients were screened for MRD treatment,
including 309 (67.5%) who were treated with an MRD, which
represents a 15e20% estimated prevalence, regarding OSA treat-
ment in this center. This estimation was based on the number of
OSA patients newly diagnosed per year in this center and treated by
either CPAP or MRD (n ¼ 400), and a time interval of four to ﬁve
years for our study (total number of patients ¼ 1600e2000). Non-
treatment reasons were mostly (n ¼ 83) dental or periodontal
contraindications toMRD use (less than eight healthy teeth per jaw,
periodontal disease and temporomandibular joint disease). Others
were lost to follow-up (n ¼ 55) or were ﬁnally treated by CPAP
(n ¼ 11). The 309 MRD-treated patients were prospectively con-
tacted and 279 were included in the study (eight patients were lost
to follow-up and 22 refused to participate) (Fig. 1). For the whole
population, the median time from treatment initiation to the start
of long-term follow-up was 1002 days (668, 1345). Median time
between the ﬁrst visit with a sleep specialist and treatment initi-
ation was 162 days (First quartile, third quartile; 89, 282 days) and
was less than three months in 26% of patients. All patients were
effectively selected for MRD treatment following the center pro-
cedures (see Section 2.1) and all had an evaluation by both sleep
and the dental specialist before treatment, and a panoramix X-ray.
Baseline clinical and demographic data, and dental parameters
evaluated by the dental specialist (dental status, dental mobility,Fig. 1. Patient ﬂow thperiodontal status, mandibular advancement from end to end in
maximum protrusion, maximal jaw propulsion, dental overjet and
dental overbite) of the 279 included patients are shown in Table 1.
3.1.1. MRD titration
Only custom-made titratable and adjustable MRD devices
approved by the French Health Technology Assessment Agency
(Haute Autorite de Sante) for OSA treatment were used. The
majority of patients (86.7%) were treated with the Narval CC™
(ResMed), a bi-block MRD made with semi-rigid plastic materials
(biocompatible polymer) and customized using high-precision
computer-aided design/computer-aided manufacturing (CAD/
CAM). Others were treated either with Somnodent™ (SomnoMed
Ltd) or Orthosom (SomnoMed Ltd), or Narval™ (ResMed) for
patients with tooth morphology unsuitable for use of the CAD/CAM
technology (eg, short teeth or removable appliance leading to
inadequate retention with CAD/CAM device). All patients had at
least one titration visit and the median number of titration visits
was two. Titration was performed in the supine position, step by
step, by replacing the connecting rod for the Narval CC™, Narval™
and Orthosom, or advancing the screw by 1 mm for the Somno-
dent™, starting at 50% of the patient's maximum mandibular
protrusion. Mandibular advancement was adjusted at each visit at
the discretion of the dental sleep specialist until the best bene-
ﬁterisk ratio between symptom resolution and tolerability was
achieved (only clinically based). At each titration visit, mandibular
advancement was continued for as long as the patient was
comfortable and there was an absence of pain. At the end of
titration, the dental specialist had referred all patients to the
sleep specialist for a clinical and polysomnographic evaluation
(short-term evaluation). Some patients had more than one poly-
somnography (repeated after MRD adjustment if efﬁcacy was not
complete on AHI), however only the last one (very end of titration)rough the study.
Table 1
Patient demographic and clinical characteristics at baseline.
Patients (n ¼ 279)
Age, years 58 (50, 64)
Female, n (%) 81 (29.0)
BMI, kg/m2 26.4 (23.9, 30.0)
BMI 30 kg/m2, n (%) 71 (25.5)
Comorbidities, n (%):
Diabetes 25 (89.6)
Arterial hypertension 94 (33.7)
Cardiovascular 53 (19.0)
Not previously treated with CPAP, n (%) 119 (42.7)
Inside network, n (%) 240 (86.0)
ESS score (0e24) 11 (7, 14)
ESS score >10, n (%) 145 (52.0)
AHI,/h 26 (19, 36)
Severity of OSA, n (%)
AHI >30/h 109 (39.1)
Mild-to-moderate AHI plus ESS >10 77 (27.6)
Mild-to-moderate AHI plus ESS 10 93 (33.3)








Dental mobility, n (%)
None 217 (77.8)
Low and limited 62 (22.2)
Overbite, mm 3.0 (2.0, 4.0)
Overjet, mm 3.0 (2.0, 4.0)
Pa, mm 4.0 (3.0, 5.0)
Maximum protrusion, mm 8.0 (6.0, 10.0)
MRD type, n (%):
Narval CC (CAD/CAM) 242 (86.7)
Narval (non-CAD/CAM) 15 (5.4)
Somnomed 13 (4.7)
Orthosom 9 (3.2)
Mandibular advancement at the end of titration, mm 7.0 (6.0, 8.0)
Number of MRD titrations, n 2.0 (1.0, 2.0)
Values are median (quartiles) or number of patients (%).
BMI, body mass index; AHI, apnea-hypopnea index, per hour; CPAP, continuous
positive airway pressure; ESS, Epworth Sleepiness Scale, MRD, mandibular reposi-
tioning device, OSA, obstructive sleep apnea, CAD/CAM, computer-aided design/
computer-aided manufacturing; Pa, mandibular advancement from end to end in
maximum protrusion.
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advancement at the end of titration and number of titrations) are
shown in Table 1.
3.1.2. Short-term evaluation extracted from patient's medical record
All patients were clinically evaluated at short-term, three to six
months after initiation of MRD therapy. At this short-term evalu-
ation, 237 patients (85%) reported good global clinical efﬁcacy with
MRD treatment and 120 (43%) had complete resolution of symp-
toms. The ESS score had decreased from 11 (7, 14) at baseline to
eight (5, 12) (p < 0.0001). Overall, 44% of those who had excessive
sleepiness (deﬁned as an ESS score >10) at baseline had an ESS
score of <10 at this evaluation. Regarding tolerability, 142 patients
(51%) did not report any side effects of MRD therapy; themajority of
side effects reported by the remaining patients were of mild
severity and did not require treatment discontinuation.
PSG data were available for 213 patients (76% of those treated),
with a median time between treatment initiation and evaluation of
104 (63, 174) days. Baseline characteristics for patients with avail-
able PSG data were similar to those in the overall population
(age 59 [50, 65] years; bodymass index 26.4 [23.8, 30.0] kg/m2; AHI
28 [20, 36]/h; AHI 30/h 43% of patients). Short-term PSG evalu-
ation was pending in 66 patients (24%) treated for 845 (506, 1210)days, but had been cancelled or delayed by the patient. A 50%
reduction in AHI was achieved in 67% of patients, irrespective of
baseline OSA severity, and the AHI during MRD therapy was nine
(ﬁve, 16)/h (p < 0.0001 vs. baseline). Individual values for AHI and
ESS scores at inclusion and at short-term evaluation in the 213
patients with PSG data are shown in Fig. 2. The efﬁcacy of the MRD,
determined as reductions in AHI to <5/h, <10/h and <15/h and by
severity of OSA is provided in Fig. 5 (supplemental appendix).
Immediately after the short-term evaluation, 15 patients (5%) dis-
continuedMRD use, seven for inefﬁcacy, four because of side effects
(dental, periodontal or articular pain, and one patient for dental
migration) and four without any speciﬁc reason.
3.2. Long-term follow-up
At the time of the study, 176 patients (63%) were still continuing
MRD treatment and 103 (37%) had stopped previously. In the 176
patients who continued MRD therapy, median treatment duration
was 928 (584, 1341) days. Long-term evaluation of efﬁcacy, toler-
ability and compliance was complete for 164 patients (12 patients
refused to complete the clinical evaluation survey); 107/164 pa-
tients had been treated for more than two years. Long-term sub-
jective compliance was excellent, with median MRD usage of seven
(six, eight) h/night on seven (six, seven) nights/week. The majority
of participants (88%) used the MRD for 4 h/night, 4 days/week,
and 73% used the device every night. The ESS score decreased from
11 (seven, 14) at baseline to ﬁve (two, eight) (p < 0.00001). There
were signiﬁcant reductions in almost all OSA symptoms (snoring,
mouth opening, headache, sleepiness, unrefreshing sleep, tired-
ness), excluding nocturia and libido disorder. Efﬁcacy over timewas
maintained for snoring, sleepiness and ESS score, but there was a
mild reduction in MRD efﬁcacy over time with respect to nocturia,
mouth opening, headache, unrefreshing sleep and tiredness.
Symptoms at inclusion and short-term and long-term evaluations
are shown in Fig. 3. MRD use was well tolerated. Overall, 106 pa-
tients (65%) did not report any side effects. Those reported by other
patients were generally of mild intensity and manageable (dental,
articular or periodontal pain [27% of patients], tooth mobility or
migration [7%], joint malfunction or occlusion [9%], and bleeding or
irritation [17%]). MRD efﬁcacy and tolerability was similar for
patients treated for <2 or 2 years. Patient satisfaction with MRD
therapy was excellent; global satisfaction score was 7.6 ± 1.6,
comfort score 7.2 ± 1.8, quality of sleep score 7.3 ± 2 and treatment
manageable score 9.5 ± 1.1. We compared these results with CPAP
scores: comfort 9.4 ± 1.6, reduction of symptoms 8.3 ± 2.4,
compliance 9.3 ± 1.5 and social life 6.8 ± 2.4. Clinical efﬁcacy, side
effects and compliance at baseline and at short-term evaluation (all
included patients, n ¼ 279) and at long-term evaluation (for those
who were continuing at the time of the study, n ¼ 164), are shown
in Table 3. For the long-term evaluation, results are shown for the
whole group (n ¼ 164, all patients were treated for more than six
months) and by subgroups for several duration of treatment, sub-
group of patients treated more than two years (n ¼ 107), subgroup
of patients treated more than three years (n ¼ 60) and subgroup of
patients treated more than four years (n ¼ 30).
In the 103 patients who stopped MRD treatment, median
treatment duration was 351 (174, 752) days (29 patients were
treated for sixmonths or less, 23 patients for sixmonths to one year,
22 patients for one to two years, 21 patients for two to three years,
seven patients for three to four years, and one patient for more than
four years). Four patients had died at the time of the prospective
contact. All were males and had stopped their MRD treatment for
intolerance prior to their death, which was secondary to oesopha-
geal cancer ([patient age 82 years], amyotrophic lateral sclerosis
[age 57 years], dementia [age 87 years, and sudden death [age 77
Fig. 2. Apnea-hypopnea index (left) and Epworth Sleepiness Scale score (right) at inclusion and at short-term evaluation on MRD, in the 213 patients having a short-term
polysomnography.
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treatment may occur after long-term device use because 29/103
patients stopped after more than two years' use. The main reasons
for stopping treatment were inefﬁcacy (26.2%), discomfort (25.2%),
side effects (21.4%) and no speciﬁc reason (27.2%). Stopping treat-
ment for no speciﬁc reason was more common in those who
stopped treatment after two years' use versus after less than two
years' use (37% vs. 23%; p ¼ 0.004), while stopping for discomfort
was less common (14% vs. 30%; p ¼ 0.01), and there were no
differences between patient subgroups for discontinuation due to
side effects (28% vs. 19%) and inefﬁcacy (21% vs. 28%).3.3. Multivariate analysis of predictive factors of long-term
continuation of MRD
The univariate analysis identiﬁed signiﬁcant predictors of long-
term MRD use (Table 2). In the ﬁrst adjusted multivariate modelincluding all patients, two factors were predictors of continuation:
MRD as ﬁrst-line therapy (ie, no previous CPAP; odds ratio [OR]
1.77, 95% conﬁdence interval [CI] 1.03e3.03; p ¼ 0.0375) and
complete symptom resolution at short-term evaluation (OR 1.78,
95% CI 1.03e3.08; p ¼ 0.0384). In the second adjusted multivariate
analysis including only patients with short-term PSG data, signiﬁ-
cant predictors of continuing MRD treatment included a 50%
reduction in AHI at short-term evaluation (OR 2.73, 95% CI
1.466e5.10; p ¼ 0.0002) and complete symptom resolution at
short-term evaluation (OR 3.83, 95% CI 1.74e8.48; p ¼ 0.0014).3.4. Replacement of MRD
At the time of the long-term follow-up, MRD replacement had
been done or was underway for 74 patients (27%). This replacement
processwas initiated after amedian of 427 (350, 533) days. TheMRD
was not replaced in the majority of patients. The median treatment
Fig. 3. Long-term efﬁcacy of MRD in patients continuing to use the device (n ¼ 164). ap<0.01 for long-term evaluation versus inclusion; bp < 0.01 for short-term versus long-term
evaluation; cp < 0.01 for short-term evaluation versus inclusion.
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54 patients (35 with a replaced MRD) after a median time from
treatment initiation of 846 (713, 1111) days. At this evaluation, the
proportion of patients with a 50% reduction in AHI was 63%.
3.5. Evaluation of resources
Resource use data were extracted in a sample of 30 patients
(ten who stopped after six months and 20 continuing patients). In
this subgroup, the mean number of attended sleep visits, attended
dental specialist visits, and polysomnographies was 4.2 ± 2.4,
5.9 ± 2.9 and 2.1 ± 1.2, respectively.Table 2







Diabetes, n (%) 14 (8) 17 (16) 0.0616
Dyslipidemia, n (%) 9 (5) 14 (14) 0.0223
Never smoker, n (%) 118 (67) 57 (55) 0.0268
MRD as ﬁrst-line therapy, n (%) 86 (49) 36 (35) 0.0179
Overbite, mm 3.5 ± 1.6 2.4 ± 1.6 0.0079
Propulsion, mm 5.1 ± 1.4 5.6 ± 1.4 0.0103
First advancement, mm 6.0 ± 1.5 6.4 ± 1.8 0.0445
Final titration, mm 6.7 ± 1.7 7.1 ± 1.7 0.0451
Short-term evaluation
Global clinical efﬁcacy, n (%) 160 (91) 75 (73) 0.0007
Complete resolution of
symptoms, n (%)
83 (47) 37 (36) 0.0673
ESS score (0e24) 8.3 ± 4.6 9.7 ± 5.2 0.0551
Somnolence, n (%) 49 (28) 44 (43) 0.0357
Snoring, n (%) 72 (41) 61 (59) 0.0559
Discomfort, n (%) 40 (23) 47 (46) 0.0006
Intolerance, n (%) 26 (15) 39 (38) 0.0002
No AEs, n (%) 84 (48) 34 (33) 0.0025
AHI reduction >50%a, n (%) 132 (75) 53 (51) 0.0006
Values are mean ± standard deviation, or number of patients (%).
AE, adverse event; AHI, apnea-hypopnea index; ESS, Epworth Sleepiness Scale;
MRD, mandibular repositioning device.
a In 213 patients with short-term PSG evaluation.4. Discussion
This study showed that MRDs can be effective and safely used
for long-term OSA therapy, with good compliance and patient
satisfaction. Our study followed patients for up to 1000 days after
initiation of MRD use and included a much larger population than
previous similar analyses [12,14,16].
This study showed good long-term persistence with MRD
use (63% at 2.5 years), accompanied by good clinical efﬁcacy,
good tolerability and excellent compliance. Although MRD
treatment efﬁcacy was effectively maintained with respect
to the most speciﬁc symptoms of OSA (ie, snoring and sleepi-
ness), treatment was less efﬁcient for the long-term control of
other symptoms, including nocturia, mouth opening, headache,
unrefreshing sleep or tiredness. This may be due to natural
progression in the severity of OSA [17], but is more likely the
result of device wear after several years' use. Current guidelines
recommend replacing an MRD after two to three years of use
but do not provide speciﬁc guidance based on changes in clin-
ical endpoints [18]. In our cohort, guidelines at the study center
indicated that the MRD should have been replaced after two
years in the 107 patients remaining on treatment at this time.
However, only 74 patients had device replacement at the long-
term follow-up. In practice, MRD replacement is not automatic
after two years and a decision to replace the device with a
new one is clinically driven and mainly based on the occur-
rence/rate of snoring and somnolence. Our results do highlight
the importance of taking other OSA symptoms (eg, nocturia,
headache, tiredness, mouth breathing during sleep or poor
quality of sleep) into account as signals of loss of MRD efﬁcacy
that may occur earlier than relapses of snoring or somnolence.
Prospective investigation into the predictive value of these
symptoms for determining the timing of MRD replacement is
an area for future research. It could be of importance to identify
a loss of efﬁcacy early on, because 26.2% of long-term stoppers
in this study discontinued due to inefﬁcacy. In addition, such
clinical predictors would be useful because guidelines do not
recommend repeating PSG over time after reaching the optimal
titration.
Table 3
Baseline and short-term evaluation for all included patients, and long-term evaluation for continuing patients at the time of the study.
Baseline n ¼ 279 Short-term n ¼ 279 Long-term evaluation in continuing patients by duration of MRD
treatment n ¼ 164
All Subgroups by time interval
>6 months >2 years >3 years >4 years
Number of patients 279 279 164 107 60 30
Snoring, n (%) 268 (96) 97 (35) 62 (38) 36 (34) 21 (35) 9 (30)
Nocturia, n (%) 135 (48) 36 (13) 93 (57) 61 (57) 36 (60) 19 (36)
Libido disorder, n (%) 21 (8) 7 (3) 3 (2) 2 (2) 1 (2) 0 (0)
Mouth opening, n (%) 113 (41) 19 (7) 28 (17) 19 (18) 12 (20) 6 (20)
Sleepiness, n (%) 189 (68) 66 (24) 50 (31) 26 (24) 14 (23) 7 (23)
Headache, n (%) 93 (33) 14 (5) 26 (16) 17 (16) 10 (17) 3 (10)
Unrefreshing sleep, n (%) 155 (56) 23 (8) 35 (21) 19 (18) 11 (18) 5 (17)
Tiredness, n (%) 186 (67) 37 (13) 55 (34) 32 (30) 15 (25) 7 (23)
ESS score >10, n (%) 145 (52) 68 (24) 28 (17) 18 (17) 9 (15) 3 (10)
No adverse events, n (%) NA 142 (51) 115 (70) 78 (73) 44 (73) 21 (70)
Dental, periodontal or articular pain, n (%) NA 40 (18) 45 (27) 27 (25) 14 (23) 8 (27)
Joint malfunction or occlusion, n (%) NA 32 (12) 15 (9) 9 (8) 5 (8) 3 (10)
Bleeding or irritation, n (%) NA 13 (5) 27 (17) 16 (15) 7 (12) 3 (10)
Dental mobility or migration, n (%) NA 15 (5) 11 (7) 8 (8) 5 (8) 2 (7)
Compliance, days/week mean ± SD NA 6.1 ± 1.8 6.1 ± 1.7 6.1 ± 1.7 6.1 ± 1.8 5.9 ± 2.0
Compliance, hour/night mean ± SD NA 6.4 ± 1.9 6.9 ± 1.2 6.9 ± 1.2 6.8 ± 1.2 6.7 ± 0.9
AHI mean ± SD 29.8 ± 16.1 12.5 ± 11.2a 14.6 ± 10.2b NA NA NA
For baseline and short-term evaluations, results were extracted from patient's medical record and are shown for all included patients (n ¼ 279).
For long-term evaluation, results were assessed prospectively and based on one contact at the time of the study. As the duration of treatment was not the same for all patients
at the time of this contact, results are shown for the whole group of continuing patients (n ¼ 164, all patients were treated at least six months) and by subgroups (cumulative
number by time intervals).
Values are number of patients (%), or mean ± standard deviation.
a Based on the 213 patients having a short-term polysomnography.
b Based on the 54 patients having a long-term polysomnography.
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cohort. However, there was a small, non-signiﬁcant increase in
dental migration or mobility between the short- and long-term
evaluations. In addition, about 21.4% of the 103 patients who
stopped MRD therapy during long-term follow did so because of
side effects. Stopping therapy due to side effects was numerically
more frequent in patients who had been using anMRD for >2 years,
even not signiﬁcant. Given that long-term occlusion changes may
occur [19], our results support regular dental follow-up as an
approach to avoid side effects and prevent treatment cessation in
long-term MRD users.
Our conservative approach for assessing long-term stopping of
MRD therapy showed that the proportion of patients who stopped
long-term MRD therapy was very similar to those generally
observed with CPAP, suggesting that MRDs are probably equivalent
to CPAP with respect to long-term adherence, although reasons for
non-adherence may be different.Fig. 4. Proportion of patients continuing MRD treatment over time.Our ﬁndings support an important role for disease chronicity on
compliance, which was similar to those reported for other chronic
diseases [20]. Our univariate analysis identiﬁed three factors
strongly associatedwith chronic diseases as predictors of continued
MRD use. Patients who continued device use were less likely to
have diabetes or dyslipidemia and were more likely to have never
smoked. Short-term efﬁcacy was also strongly predictive of
continuedMRD use, highlighting the importance of early follow-up
in OSA patients, as in other chronic diseases. We also observed a
lack of adherence to follow-up procedures, with 66 patients not
undergoing the planned short-term PSG evaluation of MRD efﬁ-
cacy, which is again probably not uncommon for patients with a
chronic disease. For these reasons we performed two different
multivariate analyses. The ﬁrst was based on clinical parameters for
the whole population, irrespective of whatever a short-term PSG
was done or not. This showed that MRD as ﬁrst-line treatment was
a strong predictor of continuation, reinforcing the link between
chronicity of disease and long-term treatment persistence; this
indicates that patients intolerant of, or non-compliant with CPAP
are more likely to also stop MRD treatment. The second multivar-
iate analysis model included patients who had undergone short-
term PSG evaluation and showed that the AHI reduction and
complete symptom resolution were strong predictors of long-term
MRD continuation. These ﬁndings reinforce the importance of
short-term follow-up and effective device titration, to ensure the
long-term success of MRD therapy. Physicians should inform their
patients of the importance of attending short-term follow-up visits,
and need to undertake additional titration in patients whose PSG
results and clinical examination indicate persistent symptoms,
particularly in those using an MRD as a second-line treatment.
Regular long-term follow-up visits are also probably important
for maintaining long-term compliance because cessation after
long-term device use is common (103 patients stopped after two
years in this study). Patients appeared to do well in terms of
V. Attali et al. / Sleep Medicine 27-28 (2016) 107e114114persisting with MRD therapy under the integrative care manage-
ment approach. Nevertheless, the process of optimal device titra-
tion required that several steps were followed over a deﬁned time
period, including visits with two specialists, MRD manufacturing
time, titration, and PSG evaluation. In our study, the median time
between MRD prescription by the sleep specialist and initiation of
treatment, and the median time between initiation and short-term
PSG evaluation were respectively 162 days and 104 days. Titration
may take longer in some patients to avoid side effects or discom-
fort. Timewithout treatment could be much longer in some centers
and could be of importance in the most severe or sleepy patients.
This is something that needs to be addressed when discussing
different therapeutic options, particularly CPAP.
This study has numbers of strengths. Long-term assessment
with at least one year of follow-up was done prospectively and
included both symptomatic evaluation and patient satisfaction.
One-year follow-up was chosen so that only patients with
optimal MRD therapy after ﬁnal titration of the device were
included. All consecutive OSA patients meeting the inclusion
criteria were systematically contacted and more than 90% agreed
(279/309) to take part in the study. Based on previously published
data on MRD efﬁcacy, the number of patients was sufﬁcient to
detect a signiﬁcant AHI reduction at the short-term assessment
[21] and to analyze long-term compliance under real-life condi-
tions in the patients continuing to use an MRD after a median of
1000 days. Although the trial design was not randomized or
comparative, the aim of the study was to evaluate MRD treatment
in a real-world setting without any inﬂuence of study-mandated
procedures. However, baseline characteristics for our patients
were comparable to those included in published randomized
studies [6,13,22].
In conclusion, persistence with MRD therapy over the long
term in patients treated under real-world conditions was good
(approximately two-thirds of patients were still using the device
after 1000 days of follow-up). In addition, MRD therapy was
effective and well tolerated, and patients were satisﬁed with
treatment. Short-term control of OSA by MAD was predictive of
long-term efﬁciency. The major criteria were a 50% reduction in
AHI and complete symptom resolution at short-term evaluation.
These results also highlight the importance of integrated, multi-
disciplinary care with regular follow-up to ensure the long-term
adherence to MRD treatment.Acknowledgements
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